- RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
For: NSCLC (Non-small Cell Lung Cancer) · Non-Small Cell Lung Cancer · NSCLCUnited States · Australia · Belgium - RecruitingPHASE3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This study is looking at a new drug, daraxonrasib, for people with pancreatic cancer that has spread. It compares daraxonrasib alone, or with standard chemotherapy (gemcitabine and nab-paclitaxel), against standard chemotherapy by itself. The aim is to see if the new treatments can help people live longer and stop the cancer from growing.
For: Pancreatic Cancer · Pancreatic Cancer Metastatic · PDACUnited States · Australia · Brazil - RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
This study is for people who have had surgery for pancreatic cancer. We are testing a new drug, daraxonrasib, to see if it can stop the cancer from coming back, compared to just being watched. It's to help see if this new treatment works better.
For: Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal AdenocarcinomaUnited States · France · Germany - RecruitingPHASE1, PHASE2
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is looking at two new medicines, Elironrasib and Daraxonrasib, for people with advanced cancers that have a specific genetic change called KRAS G12C. Researchers want to see if these medicines are safe and how well they work, both alone and together.
For: Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer · Pancreatic Ductal AdenocarcinomaUnited States · France · Germany - Not yet recruitingPHASE2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This study is for people with advanced solid tumours that have a specific genetic change called an MTAP deletion. It's testing a new medicine, BMS-986504, alone and with other cancer treatments, to see how safe and effective they are.
For: Solid TumorsUnited States · Belgium · Canada